Skip to content

Transcranial Alternating Current Stimulation (tACS) for Auditory Hallucinations

Intervention Treatment of Auditory Hallucination by Transcranial Alternating Current Stimulation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05159336
Enrollment
30
Registered
2021-12-16
Start date
2021-11-16
Completion date
2023-05-28
Last updated
2021-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Transcranial alternating current stimulation (tACS) can modulate and restore neural oscillations that are reduced in patients with psychiatric illnesses such as schizophrenia. Here, we performed a open-lable study of clinical trial in 30 schizophrenia patients with auditory hallucinations to show that tACS is effective for auditory hallucinations.

Detailed description

Each week, the patient rested quietly with her eyes open while receiving alpha-frequency tACS for 40 minutes. Stimulation was delivered at 10 Hz with 1 mA zero-to-peak amplitude in-phase to the location 1 and the location 2 acquired by the MEG technique with 5\*5 cm electrodes. A 5\* 7 cm return electrode was centered on Cz. In total, 20 weeks.

Interventions

DEVICEtACS for auditory hallucinations via single arm

a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol

Sponsors

Shanghai Mental Health Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Schizophrenia with auditory hallucinations was diagnosed by DSM-IV, AHRS \>12, Take sufficient antipsychotics for at least 1 month.

Exclusion criteria

* current pregnancy, major medical illness affecting the central nervous system, significant neurologic disorders, intake of drugs including supplements like essential fatty acids that influence prostaglandins or niacin skin flush flash pathway metabolism, a history of suicide risk, or alcohol or drug abuse.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of Auditory Hallucination Scale(the minimum is 0, maximum value is 47, and higher scores mean a worse outcome)One monthReduction rate of AHRS scale

Countries

China

Contacts

Primary ContactYegang Hu, Doctor
yeganghu@126.com021-52219305

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026